Prentice-Lewis Clinical Research Study
Continued from previous page

DISCUSSION

The survey results suggest that the perceived mental and physical health benefits reported from taking the proprietary micro-dilution oral spray Growth Factor-MMC system were significant.

While this survey was not conducted using any controls, subjects did report baseline subjective data, which provided a clear comparison for analysis of perceived effectiveness.

In addition, while participating in this study, subjects purchased the proprietary micro-dilution oral spray Growth Factor-MMC system with a 100% money back guarantee. If subjects were not satisfied with their product’s results, they had the option of requesting their money back. A condition for their refund was that subjects had to complete the survey or submit a written explanation. This ensured that subjects, regardless of their results, were motivated to complete the survey.

In order to be included in the survey, subjects needed to purchase and consistently use up at least one bottle of product, providing baseline and one-month assessments.

The length of the study did not allow for clear assessment of long-term efficacy. Survey subjects who did not respond to the product may have responded later with continued use.

SELECTED REFERENCES
Baxter, R.C. & Cowell, C.T. (1987). Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. Journal of Clinical Endocrinology and Metabolism, 65, 432-40.

Bercu, B.B., Walker, R.F. Growth Hormone Secretagogues in Clinical Practice (1998). Marcel Dekker, Inc., New York, NY.

Bowers, Cyril Y. Synergistic Release of Growth Hormone by GHRP and GHRH: Scope and Implication. Growth Hormone Secretagogues in Clinical Practice (1998). Mercel Dekker, Inc., New York, NY., pp. 1-25.

Frystyk, J., Skjaerbaek, C., Dinesen, B. & Orskov, H. (1994). Free insulin-like growth factors (IGF-1 and IGF-II) in human serum. FEBS Letters, 348, 185-91.

Hussain, M.A., Schmitz, O., Mengel, A., Glatz, Y., Christiansen, J.S., Zapf, J. & Froesch, E.R. (1994). Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. Journal of Clinical Investigation, 94, 1126-33.

Jorgensen, J.O., Moller, N. Lauritzen, T., Alberti, K.G., Orskov, H. & Christiansen, J.S. (1990a). Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. Journal of Clinical Endocrinology and Metabolism, 70, 207-141S.

Jorgensen, J.O.L., Blum, W.F., Moller, N., Ranke, M.B. & Christiansen, J.S. IGF binding protein 3 in growth hormone deficient patients and age-and sex-matched normal subjects. Acta Endocrinologica (Copenhagen), 123, 257-62.

Juul, A., Main, K., Blum, W.F., Lindholm, J., Ranke, M.B. & Skakkebaek, N.E. (1994b). The ratio between serum levels of insulin-like growth factor (IGF-1) and the IGF binding proteins (IGFBP-1, 2, and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clinical Endocrinology, 41, 85-93.

Juul, A., Jorgensen, J.O.L. Growth Hormone in Adults: Physiological and clinical aspects (1996). Cambridge University Press, Cambridge, U.K.

Minuto, F., Underwood, L.E., Grimaldi, P., Furlanetto, R.W., Van Wyk, J.J. & Giordano, G. (1981). Decreased serum somatomedin C concentration during sleep: temporal relationship to the nocturnal surges of growth hormone and prolactin. Journal of Clinical Endocrinology and Metabolism, 52, 399-403.